
Disc Medicine (IRON) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
0
Operating Income
-61.4M
Net Income
-55.2M
EPS (Diluted)
$-1.58
Balance Sheet Metrics
Total Assets
709.3M
Total Liabilities
48.9M
Shareholders Equity
660.4M
Debt to Equity
0.07
Cash Flow Metrics
Operating Cash Flow
-45.8M
Free Cash Flow
-48.0M
Revenue & Profitability Trend
Disc Medicine Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 0 | 0 | 0 | 0 | 0 |
Cost of Goods Sold | - | - | - | - | - |
Gross Profit | - | - | - | - | - |
Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Operating Expenses | |||||
Research & Development | 96.7M | 69.3M | 33.4M | 25.2M | 28.2M |
Selling, General & Administrative | 33.0M | 21.9M | 14.0M | 5.8M | 5.9M |
Other Operating Expenses | - | - | - | - | - |
Total Operating Expenses | 129.7M | 91.1M | 47.5M | 30.9M | 34.0M |
Operating Income | -129.7M | -91.1M | -47.5M | -30.9M | -34.0M |
Operating Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Non-Operating Items | |||||
Interest Income | 21.3M | 14.8M | 709.0K | 14.0K | 37.0K |
Interest Expense | 572.0K | - | - | 2.2M | 6.8M |
Other Non-Operating Income | -2.0K | -2.0K | -61.0K | -5.0M | -8.0K |
Pre-tax Income | -109.0M | -76.3M | -46.8M | -36.0M | -40.8M |
Income Tax | 355.0K | 99.0K | 0 | - | - |
Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Net Income | -109.4M | -76.4M | -46.8M | -36.0M | -40.8M |
Net Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Key Metrics | |||||
EBITDA | -108.3M | -91.0M | -47.3M | -25.9M | -33.7M |
EPS (Basic) | $-3.96 | $-3.42 | $-45.05 | $-44.90 | $-9.01 |
EPS (Diluted) | $-3.96 | $-3.42 | $-45.05 | $-44.90 | $-9.01 |
Basic Shares Outstanding | 27606022 | 22315877 | 1039490 | 801467 | 4530199 |
Diluted Shares Outstanding | 27606022 | 22315877 | 1039490 | 801467 | 4530199 |
Income Statement Trend
Disc Medicine Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 192.4M | 360.4M | 194.6M | 88.0M | 4.5M |
Short-term Investments | 297.4M | - | - | - | - |
Accounts Receivable | - | - | - | - | - |
Inventory | - | - | - | - | - |
Other Current Assets | 3.7M | 5.3M | 3.9M | 2.4M | - |
Total Current Assets | 493.6M | 365.7M | 198.5M | 90.5M | 5.1M |
Non-Current Assets | |||||
Property, Plant & Equipment | 1.6M | 1.9M | 1.4M | 1.6M | 808.0K |
Goodwill | - | - | - | - | - |
Intangible Assets | - | - | - | - | - |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 838.0K | 234.0K | 116.0K | 180.0K | 3.0M |
Total Non-Current Assets | 3.2M | 2.3M | 1.7M | 1.9M | 3.3M |
Total Assets | 496.8M | 368.0M | 200.2M | 92.4M | 8.3M |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 7.9M | 12.6M | 16.2M | 2.6M | 2.4M |
Short-term Debt | 130.0K | 665.0K | 307.0K | 319.0K | 16.7M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | - | - | - | 6.4M | - |
Total Current Liabilities | 23.3M | 21.4M | 22.6M | 13.4M | 24.9M |
Non-Current Liabilities | |||||
Long-term Debt | 29.9M | 1.4M | 1.0M | 1.3M | 5.0M |
Deferred Tax Liabilities | - | - | - | - | - |
Other Non-Current Liabilities | - | - | - | 358.0K | 277.0K |
Total Non-Current Liabilities | 29.9M | 1.4M | 1.0M | 143.2M | 5.3M |
Total Liabilities | 53.2M | 22.9M | 23.6M | 156.6M | 30.2M |
Equity | |||||
Common Stock | 3.0K | 2.0K | 2.0K | 0 | 2.0K |
Retained Earnings | -298.0M | -188.6M | -112.2M | -65.4M | -112.8M |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 443.6M | 345.1M | 176.6M | -64.2M | -21.9M |
Key Metrics | |||||
Total Debt | 30.0M | 2.1M | 1.3M | 1.7M | 21.6M |
Working Capital | 470.3M | 344.2M | 175.9M | 77.1M | -19.8M |
Balance Sheet Composition
Disc Medicine Cash Flow Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | -109.4M | -76.4M | -46.8M | -36.0M | -40.8M |
Depreciation & Amortization | 156.0K | 100.0K | 89.0K | 32.0K | 322.0K |
Stock-Based Compensation | 16.8M | 5.5M | 2.1M | 507.0K | 983.0K |
Working Capital Changes | -5.2M | -3.8M | 271.0K | 2.5M | -3.7M |
Operating Cash Flow | -97.0M | -74.3M | -44.2M | -31.4M | -36.8M |
Investing Activities | |||||
Capital Expenditures | -505.0K | -89.0K | -151.0K | -68.0K | -22.0K |
Acquisitions | - | - | - | - | - |
Investment Purchases | -386.6M | - | - | - | - |
Investment Sales | 94.8M | - | - | - | - |
Investing Cash Flow | -292.3M | -89.0K | -151.0K | -68.0K | -22.0K |
Financing Activities | |||||
Share Repurchases | - | - | - | - | - |
Dividends Paid | - | - | - | - | - |
Debt Issuance | 29.0M | - | - | 0 | 14.0M |
Debt Repayment | - | - | - | -4.6M | 0 |
Financing Cash Flow | 214.9M | 199.1M | 148.8M | 281.2M | 34.1M |
Free Cash Flow | -94.4M | -73.6M | -42.4M | -27.6M | -32.7M |
Net Change in Cash | -174.5M | 124.7M | 104.4M | 249.7M | -2.7M |
Cash Flow Trend
Disc Medicine Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
4.99
Forward P/E
-11.07
Price to Book
3.29
PEG Ratio
0.09
Profitability Ratios
Profit Margin
0.00%
Operating Margin
0.00%
Return on Equity
-26.36%
Return on Assets
-17.95%
Financial Health
Current Ratio
32.11
Debt to Equity
5.04
Beta
2.50
Per Share Data
EPS (TTM)
$-4.46
Book Value per Share
$17.70
Revenue per Share
$0.00
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
iron | 2.0B | 4.99 | 3.29 | -26.36% | 0.00% | 5.04 |
Vertex | 100.2B | 27.77 | 5.83 | 22.77% | 31.86% | 8.89 |
Regeneron | 62.9B | 14.95 | 2.06 | 15.34% | 31.37% | 9.04 |
BridgeBio Pharma | 9.6B | -17.12 | -5.28 | 36.76% | 98.25% | -1.04 |
Madrigal | 8.5B | -17.67 | 12.12 | -36.30% | -54.68% | 17.81 |
Blueprint Medicines | 8.4B | -120.99 | 24.43 | -47.71% | -27.70% | 208.50 |
Financial data is updated regularly. All figures are in the company's reporting currency.